Related Experiment Videos
Non-invasive detection of coronary artery disease by body surface electrocardiographic mapping after dipyridamole
Insights
The dipyridamole electrocardiogram (ECG) test effectively detects coronary artery disease, showing similar results to treadmill exercise tests. This method is valuable for assessing myocardial ischemia in patients with coronary artery disease.
Area of Science:
- Cardiology
- Diagnostic Imaging
Background:
- Coronary artery disease (CAD) diagnosis often relies on non-invasive stress testing.
- Dipyridamole infusion is an alternative to exercise stress testing for evaluating myocardial ischemia.
Purpose of the Study:
- To compare electrocardiographic (ECG) changes induced by dipyridamole infusion with those from submaximal treadmill exercise.
- To assess the diagnostic utility of the dipyridamole ECG test in patients with coronary artery disease.
Main Methods:
- Body surface mapping technique with 87 unipolar ECG leads was used.
- 41 patients with CAD were divided into non-myocardial infarction (MI), anterior MI, and inferior MI groups.
- Electrocardiographic changes, specifically ST-segment depression, were analyzed after dipyridamole infusion and treadmill exercise.
Main Results:
- Dipyridamole induced ischemic ST-segment depression in 61% of the total patient population, comparable to exercise (61%).
- ST depression patterns were similar between dipyridamole and exercise tests across different patient groups (non-MI, ANT-MI, INF-MI).
- The increase in pressure-rate product was significantly lower with dipyridamole compared to exercise.
Conclusions:
- The dipyridamole ECG test is as useful as the exercise ECG test for assessing coronary artery disease.
- Dipyridamole-induced myocardial ischemia is likely due to inhomogeneous distribution of myocardial blood flow.
- The findings support dipyridamole ECG testing as a viable alternative for CAD evaluation.
Abstract:
Electrocardiographic changes after dipyridamole infusion (0.568 mg/kg/4 min) were studied in 41 patients with coronary artery disease and compared with those after submaximal treadmill exercise by use of the body surface mapping technique. Patients were divided into three groups; 19 patients without myocardial infarction (non-MI group), 14 with anterior infarction (ANT-MI) and eight with inferior infarction (INF-MI). Eighty-seven unipolar electrocardiograms (ECGs) distributed over the entire thoracic surface were simultaneously recorded. After dipyridamole, ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ANT-MI group, 63% of the INF-MI group and 61% of the total population. Exercise-induced ST depression was observed in 84% of the non-MI group, 43% of the ANT-MI group, 38% of the INF-MI group and 61% of the total. For individual patients, there were no obvious differences between the body surface distribution of ST depression in both tests. The increase in pressure rate product after dipyridamole was significantly less than that during the treadmill exercise. The data suggest that the dipyridamole-induced myocardial ischemia is caused by the inhomogenous distribution of myocardial blood flow. We conclude that the dipyridamole ECG test is as useful as the exercise ECG test for the assessment of coronary artery disease.